No Data
No Data
Āshibio Announces Appointment of Dipal Doshi, CEO of Entrada Therapeutics, to Its Board of Directors
Entrada Therapeutics Price Target Maintained With a $25.00/Share by Oppenheimer
Oppenheimer Reiterates Outperform on Entrada Therapeutics, Maintains $25 Price Target
Oppenheimer Initiates Entrada Therapeutics(TRDA.US) With Buy Rating, Announces Target Price $25
Oppenheimer analyst Francois Brisebois initiates coverage on $Entrada Therapeutics(TRDA.US)$ with a buy rating, and sets the target price at $25.According to TipRanks data, the analyst has a success
Entrada Therapeutics Inc (TRDA) Gets a Buy From Oppenheimer
Entrada Therapeutics Insider Sold Shares Worth $440,801, According to a Recent SEC Filing